University of Wisconsin–Madison

Medicine for All: The Case for a Public Option in the Pharmaceutical Industry

Type Policy Brief or Report
Year 2019
Level City or Town, National, State
State(s) All States
Policy Areas Economic Justice, Health
Though the United States has a large and highly developed pharmaceutical industry, it operates on an extractive model that contributes to inequality and increasingly produces drug shortages, inefficiency, lagging innovation, misinformation and misuse of medications, and the world’s highest drug prices. These poor outcomes are the natural consequence of an industry oriented around the goal of maximizing profit above all else. This report outlines a model for a structural alternative—public ownership in the pharmaceutical sector—and offers initial considerations about the potential benefits of such a model for national health and wellbeing, the economy and democracy.

Remove Entry

Are you sure you want to remove this?

There was an error communicating with the server.

Please try again later.

There was an error while saving your data.

Please try again later.


Please try again later.

Update Page Content

You are leaving the page

Please make sure you saved all of the modules to avoid losing any data.